<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023709</url>
  </required_header>
  <id_info>
    <org_study_id>SU-33722</org_study_id>
    <secondary_id>2U19AI057229-11</secondary_id>
    <nct_id>NCT03023709</nct_id>
  </id_info>
  <brief_title>Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)</brief_title>
  <official_title>Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers. U19-HIPC Vaccination and Infection: Indicators of Immunological Health and Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators collected blood and lymphoid tissues routinely discarded during surgery
      from adults after a routine seasonal influenza vaccination to determine how immune memory
      develops at the actual site of infection, and how immunization may alter this process.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV study of licensed influenza vaccines with up to 30 male and female adults,
      18-49 years of age that was halted due to the recommendation that live, attenuated influenza
      vaccine (LAIV) not be used as a seasonal flu vaccine. Volunteers were patients undergoing
      tonsillectomy for treatment of obstructive sleep apnea (OSA).

      In the initial pilot phase of the study, up to 3 volunteers will be enrolled and will receive
      the current seasonal quadrivalent, inactivated influenza vaccine (IIV4) given intramuscularly
      to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to
      tonsillectomy. Enrollment of the remaining study volunteers into the main portion of the
      study will begin once the initial pilot phase is completed. All of the remaining study
      volunteers will be given the current year's quadrivalent, live, attenuated seasonal influenza
      vaccine (LAIV4) intranasally.

      The second study visit for all volunteers will occur at the time of the volunteer's
      tonsillectomy surgery, 3-14 days after Visit 01. A member of the surgical team will collect a
      20 mL blood sample and a sample of the resected tonsil tissue that would otherwise be
      discarded to be distributed to the lab.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the ACIP guidelines halting the use of LAIV
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3-5 participants will receive quadrivalent inactivated flu (IIV4) vaccine as a pilot study to establish protocols for immune cell isolation. Once the pilot study ends, all new participants will receive live, attenuated influenza vaccine and IIV4 will no longer be utilitzed.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Received Influenza Vaccine</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>Day 0 to 14 post-immunization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Pilot phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone速 given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist速 intranasally 3-14 days prior to tonsillectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone速</intervention_name>
    <description>quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
    <arm_group_label>Pilot phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist速</intervention_name>
    <description>quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
    <arm_group_label>Study phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Generally healthy 18-49 year old male and female patients undergoing tonsillectomy for
             obstructive sleep apnea.

          2. Willing to complete the informed consent process

          3. Availability for follow-up for the planned duration of the study

          4. Acceptable medical history by review of inclusion/exclusion criteria

        Exclusion Criteria:

          1. Prior off-study vaccination with seasonal influenza vaccine within three months of
             study vaccination

          2. Life-threatening reactions to previous influenza vaccinations

          3. Asthma (contraindication for receipt of LAIV4) for study volunteers; not a
             contraindication for enrolling as a pilot phase volunteer receiving IIV4.

          4. Allergy to egg or egg products or to vaccine components (including gentamicin,
             gelatin, arginine or MSG for participants receiving LAIV4).

          5. Active systemic or serious concurrent illness, including febrile illness on the day of
             vaccination

          6. History of immunodeficiency (including HIV infection)

          7. Known or suspected impairment of immunologic function; may include significant liver
             disease, diabetes mellitus treated with insulin or moderate to severe renal disease

          8. Hospitalization in the past year for congestive heart failure or emphysema.

          9. Chronic Hepatitis B or C.

         10. Recent or current use of immunosuppressive medication, including systemic
             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible).
             Use of oral steroids (&lt;20mg prednisone-equivalent/day) may be acceptable after review
             by the investigator.

         11. Participants who care for severely immunosuppressed persons that require a protective
             environment should not receive LAIV, or should avoid contact with such persons for 7
             days after receipt, given the theoretical risk for transmission of the live attenuated
             vaccine virus to close contacts. [If yes, may be ineligible]

         12. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
             such as breast cancer or prostate cancer with recurrence in the past year, and any
             hematologic cancer such as leukemia).

         13. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
             of the investigator might jeopardize volunteer safety or compliance with the protocol.

         14. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
             medical follow up or hospitalization during the preceding year

         15. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox will be
             reviewed by investigators to determine if study participation would affect the
             volunteer's safety or compliance with the protocol.

         16. Has taken an influenza antiviral medication within 48 hours prior to study vaccination
             [For volunteers receiving LAIV; If yes, may not eligible if unable to schedule at an
             appropriate interval].

         17. Receipt of blood or blood products within the past 6 months or planned use during the
             study.

         18. Medical or psychiatric condition or occupational responsibilities that preclude
             participant compliance with the protocol

         19. Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned
             vaccinations prior to completion of last study visit (~ 14 days after study
             vaccination)

         20. Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned
             vaccination prior to completion of last study visit (~ 14 days after study enrollment)

         21. Need for allergy immunization (that cannot be postponed) until after the last study
             visit.

         22. History of Guillain-Barr辿 syndrome

         23. Pregnant woman;

         24. Breastfeeding woman [if volunteer will receive LAIV4]

         25. Use of investigational agents within 30 days prior to enrollment or planned use during
             the study.

         26. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or
             donation of platelets within 2 weeks of enrollment or planned donation prior to
             completion of the last visit.

         27. Any condition which, in the opinion of the investigator, might interfere with
             volunteer safety, study objectives or the ability of the participant to understand or
             comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia Dekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Davis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <results_first_submitted>January 19, 2017</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Cornelia L. Dekker</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Quadrivalent inactivated influenza vaccine</keyword>
  <keyword>Quadrivalent live, attenuated influenza vaccine</keyword>
  <keyword>Adults with obstructive sleep apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was halted after the IIV pilot phase because the LAIV vaccine for the study phase was not recommended for use by ACIP so no participants enrolled in the LAIV study phase.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pilot Phase (IIV4)</title>
          <description>Participants will receive the seasonal quadrivalent, inactivated influenza vaccine (IIV4), Fluzone速, given intramuscularly to confirm the safety of administering licensed seasonal influenza vaccine 3-14 days prior to tonsillectomy.
Fluzone速: quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
        </group>
        <group group_id="P2">
          <title>Study Phase (LAIV4)</title>
          <description>Participants will be given the quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4), FluMist速, intranasally 3-14 days prior to tonsillectomy.
FluMist速: quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pilot Phase (IIV4)</title>
          <description>Participants will receive the seasonal quadrivalent, inactivated influenza vaccine (IIV4), Fluzone速, given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
Fluzone速: quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
        </group>
        <group group_id="B2">
          <title>Study Phase (LAIV4)</title>
          <description>Participants will be given quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4), FluMist速, intranasally 3-14 days prior to tonsillectomy.
FluMist速: quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7.93"/>
                    <measurement group_id="B3" value="32" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Received Influenza Vaccine</title>
        <time_frame>Day 0</time_frame>
        <population>Study halted after Pilot Phase</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Phase</title>
            <description>Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone速 given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
Fluzone速: quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
          </group>
          <group group_id="O2">
            <title>Study Phase</title>
            <description>Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist速 intranasally 3-14 days prior to tonsillectomy.
FluMist速: quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Influenza Vaccine</title>
          <population>Study halted after Pilot Phase</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <time_frame>Day 0 to 14 post-immunization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pilot Phase (IIV4)</title>
            <description>Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone速 given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
Fluzone速: quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
          </group>
          <group group_id="O2">
            <title>Study Phase (LAIV4)</title>
            <description>Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist速 intranasally 3-14 days prior to tonsillectomy.
FluMist速: quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pilot Phase (IIV4)</title>
          <description>Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone速 given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
Fluzone速: quadrivalent, inactivated influenza virus vaccine, intramuscular</description>
        </group>
        <group group_id="E2">
          <title>Study Phase (LAIV4)</title>
          <description>Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist速 intranasally 3-14 days prior to tonsillectomy.
FluMist速: quadrivalent, live, attenuated influenza vaccine, intranasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cornelia Dekker</name_or_title>
      <organization>Stanford University School of Medicine, Dept. of Pediatrics</organization>
      <phone>650-724-4437</phone>
      <email>cdekker@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

